Article
Weekly neoadjuvant chemotherapy with docetaxel (Taxotere) achieved aPSA response in almost 80% of a small group of high-risk prostate cancerpatients enrolled in a feasibility study of single-agent therapy.
Stay current with the latest urology news and practice-changing insights — sign up now for the essential updates every urologist needs.